Huadong Medicine’s ROR1 ADC HDM2005 Granted FDA Fast Track Designation — First Domestic ROR1 ADC to Achieve the Status
Huadong Medicine (SHE: 000963) announced that its investigational drug HDM2005 has been granted Fast Track...
Micot’s First‑in‑Class TrkB Agonist MT200605 Meets Primary Endpoint in Phase 2 Acute Ischemic Stroke Trial
Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKG: 2355) announced that the Phase 2 trial of...
NMPA Suspends Sales and Use of Pierre Fabre’s Encorafenib Capsules Over Unapproved Manufacturing Change
The National Medical Products Administration (NMPA) issued a notice ordering the immediate suspension of sales...
China’s NHSA Issues Guiding Opinions Establishing Unified Payment Management for Long‑Term Care Insurance (LTCI)
The National Healthcare Security Administration (NHSA) issued the Guiding Opinions on Improving the Payment Management...
Junshi Biosciences Achieves First‑Ever Semiannual Profitability as Toripalimab Sales Surge 36%
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced its unaudited interim results for...
Astellas Doses First Patient in Phase 3 Trial of Bispecific ASP2138 for First‑Line Gastric Cancer
Astellas Pharma Inc. (TYO: 4503) announced that the first patient has been dosed in a...
Shionogi Terminates Collaboration with SUSMED on Digital Insomnia Therapy Med CBT‑i
Shionogi & Co., Ltd. (TYO: 4507) announced that it has terminated its collaboration with SUSMED...
FDA Approves Revolution Medicines’ Rasonque (daraxonrasib), an Oral Multi‑Selective RAS(ON) Inhibitor, for Metastatic Pancreatic Cancer
The U.S. Food and Drug Administration (FDA) has approved Revolution Medicines’ Rasonque (daraxonrasib) for the...
NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer
Novartis (NYSE: NVS) announced that the National Medical Products Administration (NMPA) has approved the radioligand...
FDA Approves J&J’s IMAAVY for Warm Autoimmune Hemolytic Anemia, Marking Second Indication for Nipocalimab
Johnson & Johnson (J&J, NYSE: JNJ) announced that the US FDA has approved the second...
FDA Approves BeOne’s Tevimbra Plus Zanidatamab and Chemotherapy for First‑Line HER2‑Positive Gastroesophageal Adenocarcinoma
BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced that the US FDA has...
MHLW Approves Takeda’s First‑in‑Class ORZEYFUL (Oveporexton) for Narcolepsy Type 1 in Japan
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that the Japanese Ministry of Health,...
WuXi Biologics 2026H1 Revenue Climbs 18.4% to RMB 11.8 Billion as Project Pipeline Hits 1,064 Integrated Programs
WuXi Biologics (HKG: 2269) announced its interim results for the six months ended 30 June...
Fosun Pharma 2026H1 Revenue Rises 4.75% to RMB 20.44 Billion as Innovative Drugs and Globalization Power Growth
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced its interim results for...
Takeda and Ant Group Form Digital Healthcare Partnership to Advance AI‑Driven Patient Care in China
Takeda Pharmaceutical Company Limited China (TYO: 4502; NYSE: TAK) entered into a partnership agreement with...
EC Approves Gilead’s Trodelvy Plus Keytruda for First‑Line PD‑L1‑Positive Metastatic TNBC – 35% Reduction in Progression Risk
Gilead Sciences (NASDAQ: GILD) announced that the European Commission (EC) has granted marketing authorisation for...
Haisco Signs Exclusive Licensing Deal with Sentivera for Preclinical Autoimmune Asset – Up to USD 1.46 Billion in Milestones
Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that it has signed an exclusive licensing...
GSK’s Jemperli Wins FDA Priority Review for dMMR/MSI‑H Locally Advanced Rectal Cancer – PDUFA Date Set for February 2027
GlaxoSmithKline Plc (GSK, NYSE: GSK) announced that the US Food and Drug Administration (FDA) has...
Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA
The U.S. Court of Appeals for the Third Circuit ruled against Merck & Co., Inc....
WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4%
WuXi XDC (HKG: 2268) reported interim results for the first half of 2026 on Aug....